Clinical Trials Browser

Has results × Neoplasms by Site × Nivolumab × Clear all

NCT01968109 2026-01-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase 1/2 Completed

1,482 enrolled 56 charts

Neoplasms by Site